Arcellx Announces Late-Breaking Presentation at TANDEM Demonstrating Unique, High Target-Specificity of anito-cel’s D-Domain Binder
Arcellx, Inc. (ACLX)
Company Research
Source: Business Wire
-- CAR constructs representative of anito-cel (D-Domain), cilta-cel (dual VHH), and ide-cel (scFv) were assessed preclinically for tonic signaling and off-target Claudin binding ---- No tonic signaling or off-target activity was observed with the D-Domain, supporting its unique target-specific binding profile and anito-cel’s potentially best-in-class safety profile ---- Specific off-target activity against Claudin-9 was observed with the dual VHH binder, consistent with cilta-cel’s publicly available regulatory assessment reports; the D-Domain and scFv binders did not demonstrate off-target activity ---- CAR T activation and cytokine release were observed for dual VHH and scFv binders in the absence of BCMA antigen, but not with the D-Domain, supporting lack of tonic signaling for anito-cel ---- Data to be presented February 5 during the 2026 Tandem Meetings in Salt Lake City, UT -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company focused
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx (ACLX) Declined Despite Positive Clinical Trial Results [Yahoo! Finance]Yahoo! Finance
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.MarketBeat
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.MarketBeat
- Assessing Arcellx (ACLX) Valuation After Recent Share Price Swings And Conflicting P/B And DCF Signals [Yahoo! Finance]Yahoo! Finance
- Is Arcellx (ACLX) Still Attractively Priced After Strong Multi Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 2/5/26 - Form SCHEDULE
- 1/20/26 - Form 4
- 1/20/26 - Form 144
- ACLX's page on the SEC website